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Abstracts / International Journal of Surgery 36 (2016) S31eS132 S123Aim: Intravesical injections of botulinium toxin type A can be offered for
refractory symptoms of overactive bladder. This project aimed to:
(1) Assess patient satisfaction with intravesical injections admin-
istered under local anaesthetic.
(2) Evaluate service change within this Regional Unit.
(3) Use outcome tso improve service delivery.
Method: 38 patients received injections under LA November-April 2014.
During post-treatment telephone review, patients completed:
(i) the validated TSQM patient satisfaction questionnaire
(ii) a ‘recommend to a friend’ Analogue Scale
(iii) a Likert-type scale for LA versus GA
Quality of life pre and post-procedure was evaluated using ICIQ-LUTS.
Four-domain TQSM scores were calculated. T-Test was performed on pre-
and-post injection LUTS scores.
Result: Twenty-ﬁve patients were successfully contacted. Validated TSQM
questionnaires revealed a mean of 80% of the maximum score for clinical
effectiveness (SD 21). Overall global satisfaction was 78%. Fifty-six percent
of patients indicated a preference for GA compared with LA. Patients
expressing a preference for LA had greater symptom improvement.
Conclusion: Botox injections administered under LA were effective,
demonstrated by the improvement in LUTS scores and the high level of
satisfaction. A majority expressed a preference for LA; the greater symp-
tom improvement in this group may be a confounding factor.http://dx.doi.org/10.1016/j.ijsu.2016.08.454
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Introduction:Accurate risk stratiﬁcation of patients pre-biopsy is essential
for the diagnosis of prostate cancer (PCa). The objective of this studywas to
build a risk calculator to facilitate the decision for prostate biopsy in
Ireland.
Method: The clinical information of 4,808 patients from 8 Irish tertiary
centres was analysed. A risk calculator for the diagnosis of PCa and another
for the diagnosis of high grade (Gleason 7) PCa were created via logistic
regression. The components of the risk calculators are age, digital rectal
examination, family history, prior negative biopsy and PSA level.
Result: The Irish PCa Risk Calculator achieved AUC values of 0.67 and 0.73
in the prediction of PCa and high grade PCa respectively. This was a sta-
tistically signiﬁcantly improvement over PSA (p<0.01) with AUC values for
PSA of 0.60 and 0.66 for the prediction of PCa and high grade PCa. The Irish
PCa risk calculator also demonstrated a net beneﬁt on decision curve
analysis and a suitable calibration in each cohort.
Conclusion: An Irish PCa risk calculator created from a national collection
of patients can allow for individualised risk stratiﬁcation and can be used
to improve clinical decision-making in Irish men under investigation for
PCa.http://dx.doi.org/10.1016/j.ijsu.2016.08.455
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Ireland; 4 Irish Prostate Biopsy Collaborative, Dublin, Ireland.Introduction: In order to diagnose prostate cancer (PCa) effectively, the
best possible risk factors should be utilised. We assessed the performance
of two well-validated PCa risk calculators to analyse the use of prostate
volume and a novel PCa biomarker (pro-PSA) in PCa prediction.
Method: The risk of high-grade PCa (Gleason 7) in 2,001 patients from 6
tertiary referral centres was calculated according to the two PCa risk cal-
culators. Predictions were analysed using ROC analysis, calibration analysis
and decision curve analysis. In a subset of 222 patients, risk predictions
were calculated that included pro-PSA.
Result: The addition of prostate volume signiﬁcantly improved the per-
formance of high-grade PCa prediction, with an AUC of 0.74 compared to
0.69 (p<0.001). The addition of pro-PSA further improved risk prediction
with an AUC of 0.78 compared to 0.72 (p¼0.04).
Conclusion: The performance of these PCa risk calculators demonstrates
that prostate volume has the potential to improve PCa diagnosis. Further-
more, the incorporation of the pro-PSA allowed each patient’s risk to be
more accurately quantiﬁed. Individual patient risk calculation using prostate
volume and pro-PSA can be undertaken in order to allow for a systematic
approach to patient risk stratiﬁcation and to aid in the diagnosis of PCa.http://dx.doi.org/10.1016/j.ijsu.2016.08.456
0376: REJECTING REFERRALS FOR ASYMPTOMATIC NON-VISIBLE HAE-
MATURIA: IMPLICATIONS OF A CHANGE IN PRACTICE
M. Kamarizan*, A. Cox, M. Hunter, J.R. Wilson, D.J. Painter, A.C. Carter. Royal
Gwent Hospital, Newport, UK.
Introduction: The NICE NG12 guidance for urgent suspected cancers(USC)
suggests that asymptomatic non-visible haematuria(aNVH) need not be
seen as USC. Whilst implementing NG12, we also present the early
outcome of rejecting referrals for aNVH entirely.
Method: USC haematuria referrals to a large district general hospital from
April to November 2015 were strictly vetted prospectively against NG12
recommendations, and compared to data from a similar time period prior to
implementation. Simultaneously aNVH referrals were rejected in writing.
Result: In 8 months, 676 patients were seen in a one stop haematuria clin-
ic(OSHC); 352 pre-NG12 implementation(cohort 1), and 324 after-
wards(cohort 2). In cohort 1, 212 had visible haematuria(VH), and 140 had
non-visible haematuria(NVH) with 34 cancers diagnosed. Thirteen of these
were either high risk non-muscle invasive(HRNMIBC) or muscle invasive(-
MIBC)bladdercancer.Of thosewithNVH,only1 lowrisknon-muscle invasive
bladder cancer(LRNMIBC) was diagnosed. In cohort 2, 39 cancers were
diagnosed; 11 HRNMIBC and 4 MIBC. Seventy-six aNVH referrals were
rejected.Average referral to treatment timeimprovedfrom39days to18days.
Conclusion: No signiﬁcant tumour was found in patients referred with
aNVH pre-implementation. After implementation, and rejecting patients
with aNVH, patients with bladder cancer were seen and treated earlier.http://dx.doi.org/10.1016/j.ijsu.2016.08.457
0433: PROCEDURES FOR PENILE STRICTURES: OPTIONS AND OUT-
COMES AT 7 YEARS
D. Evans*, I. Rudd, R. Krishnan. Kent & Canterbury Hospital, Canterbury, Kent,
UK.
Aim: Penile urethral strictures can be treated by a variety of procedures,
often in tertiary care centres. We present our experience and outcomes
over a 7 year period at a District General Hospital.
Method: Between November 2008 and December 2015, 101 operations
were performed by a single surgeon in seventy patients with penile ure-
thral strictures. Twenty also had bulbar urethral involvement. Procedures
included two-stage urethroplasty with buccal mucosal graft (BMG) (49
ﬁrst/31 second stage), single stage dorsal BMG urethroplasty (4), Orandi
patch (5), meatotomy (7), and perineal urethrostomy (5). Median age was
51.3 years and median stricture length was 5cm.
Result: 30% of penile strictures were iatrogenic, 30%were BXO-related, and
24% were failed hypospadias repairs. A successful outcome was seen in
90%. Four patients (5.7%) required minor revision prior to ﬁnal
